NEW YORK (GenomeWeb News) – Bruker today reported that its third-quarter revenues increased 7 percent year over year, easily beating consensus Wall Street estimates on the top and bottom line.

The Billerica, Mass.-based scientific instruments maker reported total revenues of $447.8 million for the three months ended Sept. 30, compared to $418.4 million. Analysts, on average, had forecasted $421.4 million in sales.

Excluding the effects of acquisitions and foreign currency translation, Bruker's Q3 revenues were up 14 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.